Prof. David Nutt

Professor David Nutt, a cognitive sciences, addiction, cannabis and psychedelics researcher, has been ranked the #1 psychopharmacologist by ScholarGPS, a California-based American company owned and operated by Meta Analytics LLC.  According to the platform’s definition, Highly...

British neuropsychopharmacologist professor David Nutt is in Australia advocating for the use of regulatory-approved and evidence-based psychedelic-assisted therapies along with the nonprofit Mind Medicine Australia (MMA.) "There's a ridiculous resistance to accepting the fact...

Israeli psychedelics biotech Clearmind Medicine Inc. (NASDAQ: CMND) is commencing the production of its proprietary drug candidate based on the MEAI molecule. It will be used in the upcoming Phase 1 clinical trial assessing the treatment of Alcohol Use Disorder (AUD). "Like other addictions,...

(Part one of a four-part series) In recent years, evidence supporting the use of psychedelics for the treatment of unmet mental health disorders such as PTSD, depression, addictions and anxiety has done nothing but grow. Let’s dive into one of the substances emerging as potentially more...

Biopharma company Algernon Pharmaceuticals Inc's (OTC: AGNPF) recently announced plan for a Phase 1 clinical study on DMT for human stroke has just received approval from the Stichting Beoordeling Ethiek Biomedisch Onderzoek (BEBO), an independent Medical Research Ethics Committee....

Registered charity Mind Medicine Australia (MMA) seeks to help alleviate the suffering and suicide caused by mental illness through expanding novel treatment options to medical practitioners and patients. To that end, it has received new funding support for the development of...

A group of 15 top psychiatrists are addressing the Royal College of Psychiatrists’s president Dr. Adrian James to back the campaign calling for the nation’s Home Office department to move psilocybin from Schedule 1 to Schedule 2, which would remove "unnecessary and burdensome...

The research renaissance into the neuroscience and therapeutic applications of psychedelics represents one of the most promising initiatives in brain science and neuropsychopharmacology, given the huge unmet needs in the therapeutic areas they aim to treat. Actually, the fundamental...

Global Developments in Germany, Canada and Brazil Germany has approved a large phase 2b study on psilocybin for treatment-resistant depression. Dr. Gerhard Gründer, of the Central Institute of Mental Health Mannheim, will lead the study alongside the Department of Psychiatry and...